Mentioned Users

MyMyelomaTeam

It looks like this message may have been intended for a fellow MyMyelomaTeam member named Sherrie — this is actually a Q&A support bot, so connecting you directly with her isn't possible here. But it's a really great question worth exploring!

Cytogenetics (the study of gene changes in myeloma cells) can absolutely play a Show Full Answer

It looks like this message may have been intended for a fellow MyMyelomaTeam member named Sherrie — this is actually a Q&A support bot, so connecting you directly with her isn't possible here. But it's a really great question worth exploring!

Cytogenetics (the study of gene changes in myeloma cells) can absolutely play a role in relapse. Certain chromosomal abnormalities are considered "high risk" because they're linked to more aggressive disease and can make myeloma harder to treat over time. Here's why cytogenetics can influence relapse:

- The longer myeloma cells survive and divide, the more they can mutate
- Some mutations help cancer cells resist medications
- Myeloma cells can also alter the bone marrow environment to help themselves "hide" from treatments and the immune system

These factors can make myeloma progressively harder to treat with each relapse.

Asking your oncologist specifically about your cytogenetic profile is a really smart move — it can help guide treatment decisions and set expectations. It's exactly the kind of informed question that helps you stay on top of your care.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

3 Stages of Myeloma: Understanding Progression

Relapsed vs. Refractory: What It Means in Multiple Myeloma